Mohamadizadeh 2017.

Study characteristics
Methods	16 sessions trial with 3 arms Dialectical behavior therapy (DBT) Schema therapy (ST) Control (no intervention) Duration of trial: 16 sessions Country: Iran Setting: inpatient
Participants	Method of recruitment of participants: convenience sampling method Sample size: 36 Diagnosis of borderline personality disorder: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM‐IV) Means of assessment: Structured Clinical Interview for DSM‐IV Axis II Disorders (SCID‐II) Mean age: not stated Sex: 100% female Comorbidity: not stated Inclusion criteria: not stated Exclusion criteria Patients with previous suicide attempt or recurrent suicidal behaviour People with perturbations, such as bipolar disorder, substance abuse and personality disorder, treated with the drug were initially excluded.
Interventions	Experimental group 1 Treatment name: DBT Number randomised to group: 12 Duration: 16 sessions for 90 minutes Experimental group 2 Comparison name: ST Number randomised to group: 12 Duration: 16 sessions for 90 minutes Control/comparison group Comparison name: no treatment Number randomised to group: 12 Duration: 16 sessions for 90 minutes Both groups Concomitant psychotherapy: none Concomitant pharmacotherapy: none; "The use of any psychiatric medication during training, from the very first session of treatment, and the use of any type of psychological services were abandoned." (quote, p 1027) Proportions of participants taking standing psychotropic medication during trial observation period: equal (medication not allowed)
Outcomes	Primary Suicide‐related outcomes, assessed by the Beck Scale for Suicidal Ideation, suicidal thoughts subscale (BSS) Secondary Depression, assessed by the Beck Depression Inventory (BDI)
Notes	Sample size calculation: not stated Ethics approval: not stated Comments from review authors: none
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: insufficient information. It was unclear if the no treatment control group were randomized or not
Allocation concealment (selection bias)	Unclear risk	Comment: insufficient information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: insufficient information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: no attrition rates reported; no imputation methods reported
Selective reporting (reporting bias)	Unclear risk	Comment: no protocol found, so we could not compare planned methods with reported methods
Other bias	Unclear risk	Adherence to treatment Comment: no adherence check stated, but a list over each session was provided Attention bias Comment: no differences between groups Allegiance bias Comment: none